Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study

Table 2 Crude event rates and estimated hazard ratios during the 1-year post-discharge period in patients with type 2 diabetes who hospitalized for acute heart failure

	SGLT2i (N = 818)		Non-use (N = 28,472)		Crude HR (95% CI)	Weighted HR^‡ (95% CI)
	Events, N	IR ^†	Events, N	IR ^†	Crude HR (95% CI)	Weighted HR^‡ (95% CI)
Composite outcome	183	26.9	7,216	31.7	0.87 (0.75-1.00)	0.90 (0.87–0.93)
HF readmission	176	25.9	6,956	30.5	0.86 (0.74-1.00)	0.89 (0.86–0.92)
Cardiovascular death	15	1.9	746	2.8	0.70 (0.42–1.16)	0.64 (0.57–0.72)

† The number of events per 100 person-years
‡ Inverse probability of treatment weighting on the propensity score with asymmetrical trimming was used to balance comparison groups on indicators of baseline characteristics. This method produced a weighted pseudo sample of patients in the exposed and reference group with the same distribution of measured covariates
Abbreviations: CI, confidence interval; HF, heart failure; HR, hazard ratio; IR, incidence rate; SGLT2i, sodium-glucose co-transporter 2 inhibitor

ISSN: 1475-2840